Screener
AbCellera Biologics Inc. ABCL EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from AbCellera Biologics Inc.’s reported figures.
Based on trailing twelve months.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s EBITDA margin?
- AbCellera Biologics Inc. (ABCL) reported EBITDA margin of -302.2% in Q2 2026.
- How has AbCellera Biologics Inc.'s EBITDA margin changed year-over-year?
- AbCellera Biologics Inc.'s EBITDA margin increased by 56.6% year-over-year, from -696.1% to -302.2%.
- What is the long-term trend for AbCellera Biologics Inc.'s EBITDA margin?
- Over 4 years (2020 to 2025), AbCellera Biologics Inc.'s EBITDA margin has grown at a 39.3% compound annual growth rate (CAGR), from 69% to -259.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about AbCellera Biologics Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude